Every 10-Q that Medicinova (MNOV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MNOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNOV filings page.
MediciNova, Inc. reported Q2 2026 revenue of $458,439, all from research services supporting an ALS study for Mayo Foundation. For the first six months of 2026, revenue was $645,423. Net loss narrowed to $2.3 million in Q2 and $4.9 million year-to-date.
Research, development and patents expense declined to $1.0 million in Q2 and $2.3 million for the first half, mainly from lower MN‑166 and MN‑001 clinical costs, while general and administrative expenses rose to $1.8 million in Q2 and $3.4 million year-to-date due to higher professional fees and stock-based compensation.
Cash and cash equivalents were $25.4 million at June 30, 2026, with working capital of $23.0 million. Management states this is sufficient to fund operations at least through November 2027, though the company expects continued losses as it advances MN‑166 and MN‑001 and may seek additional equity financing under existing shelf arrangements.
MediciNova reported another operating loss for the quarter ended March 31, 2026 as it continues to invest in its pipeline. Revenue was $186,984, up from zero a year earlier, reflecting services under its Mayo ALS research agreement. Operating expenses were $3.0 million, slightly lower than $3.2 million in 2025 as research, development and patent costs declined to $1.3 million while general and administrative expenses rose to $1.6 million.
Net loss narrowed to $2.6 million, or $0.05 per share, compared with a $2.9 million loss, or $0.06 per share, a year earlier. Cash and cash equivalents were $27.3 million at March 31, 2026, down from $36.6 million a year ago, after $3.5 million of operating cash outflows in the quarter.
Management continues to focus on developing MN-166 (ibudilast) for several neurological indications and MN-001 (tipelukast) for fibrotic and metabolic diseases. The company reports working capital of $25.1 million and believes its current cash resources can fund operations at least through May 2027.
MediciNova (MNOV) filed its Q3 2025 10‑Q, reporting modest service revenue and a wider operating loss. Revenue was $123,319, reflecting work under its Mayo agreement for ALS research. Net loss was $3,050,373, or $0.06 per share. Operating expenses were $3,504,317, with research, development and patents at $1,582,975 and general and administrative at $1,806,070, the latter elevated by Standby Equity Purchase Agreement (SEPA) fees.
Cash and cash equivalents were $32,562,612, down from $40,359,738 at year‑end, as operating cash outflows totaled $7,793,264 for the nine months. Stockholders’ equity was $43,964,756. The company recorded $521,899 of deferred revenue from Mayo and recognized $257,918 of revenue year‑to‑date. Interest income declined to $340,850 in the quarter as cash balances fell.
Liquidity and capital access: management states cash is sufficient to fund operations at least through November 2026. In July, MediciNova established a $30.0 million SEPA with Yorkville (97% of the lowest three‑day VWAP pricing mechanism; 19.99% Exchange Cap at 9,804,345 shares), and also maintains a $75.0 million ATM; no shares were sold under either program year‑to‑date. Shares outstanding were 49,046,246 as of November 10, 2025.
Medicinova, Inc. reports key disclosures including business risks, capital structure, segment reporting and recent lease and equity arrangements. The company lists numerous risk factors such as inability to raise capital, failure to generate product revenues, clinical trial delays or failures, reliance on its MN-166 (ibudilast) and MN-001 (tipelukast) product candidates, dependence on third parties for trials, manufacturing and commercialization, intellectual property disputes, and international and regulatory risks. Common stock authorized is 100,000,000 shares with 49,046,246 shares issued and outstanding at June 30, 2025 and December 31, 2024. The CODM evaluates performance using consolidated net loss and functional expenses. The company amended its Tokyo office lease to a 14-month term for measurement purposes using a 6.51% incremental borrowing rate. There were 970,000 performance options outstanding tied to 2025 objectives and Black-Scholes inputs are disclosed. An equity sale agreement pays 3.5% of gross proceeds to the agent. The company states strategic priorities to develop MN-166 and MN-001 and pursue non-dilutive financing and partnerships.